KMDA — KAMADA LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1567529 ·
Last close
$8.62
Market Cap
$497.46M
52W High
$8.96
52W Low
$6.18
ADV30
167,928
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 54,921,000 | 22,467,000 | 9,510,000 | 9,262,000 | 383,162,000 | 29,473,000 | 113,604,000 |
| Mar 2026 | 45,240,000 | 19,116,000 | 6,953,000 | 4,132,000 | 383,021,000 | 32,922,000 | 123,634,000 |
| Dec 2025 | 44,678,000 | 16,967,000 | 3,551,000 | 3,562,000 | 378,710,000 | 75,469,000 | 109,640,000 |
| Sep 2025 | 47,010,000 | 19,762,000 | 7,816,000 | 5,296,000 | 377,210,000 | 71,997,000 | 111,978,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$25,712,000
Investing CF
$-49,576,000
Financing CF
$-18,908,000
CapEx
$-9,351,000
Dividends Paid
$-11,534,000
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-27,363,000
Inventory
$85,437,000
Receivables
$40,651,000
ST Investments
$40,225,000
EBIT TTM
$23,105,000
Pretax Income TTM
$22,245,000
Interest Exp TTM
$860,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$191,848,992
EBITDA
$41,494,000
Free Cash Flow
$15,506,375
Enterprise Value
$400,136,992
Total Cash
$70,133,000
Total Debt
$11,801,000
Shares Out
57,710,305
Trailing EPS
$0.38
Book Value
$4.66
ROE
8.4%
ROA
4.6%
Div Yield
2.14%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 180,460,000 | 26,233,000 | 20,198,000 | 378,710,000 | 109,640,000 | 269,070,000 | 25,490,000 |
| Dec 2024 | 160,953,000 | 20,051,000 | 14,462,000 | 372,255,000 | 112,791,000 | 259,464,000 | 47,594,000 |
| Dec 2023 | 142,519,000 | 10,064,000 | 8,284,000 | 354,907,000 | 110,886,000 | 244,021,000 | 4,315,000 |
| Dec 2022 | 129,339,000 | 4,532,000 | -2,321,000 | 322,379,000 | 146,359,000 | 176,020,000 | 28,586,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.60
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $8.62 · call volume: 32 · put volume: 1
Expected Move to 2026-10-16:
±$2.71
(31.44%) —
implied range
$5.91 –
$11.33
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCS | Oculis Holding AG | $503.08M | $9.06 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $506.39M | $8.71 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $506.89M | $51.66 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $506.91M | $9.82 | — |
| ARVN | ARVINAS, INC. | $484.55M | $7.51 | — |
News headlines (Yahoo Finance, 1h cache)
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
2026-09-27 12:01 · Yahoo
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
2026-09-17 11:00 · Yahoo
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 11:00 · Yahoo
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
2026-09-03 20:01 · Yahoo
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
2026-08-17 11:00 · Yahoo
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
2026-08-14 16:45 · Yahoo
KMDA or PRTA: Which Is the Better Value Stock Right Now?
2026-08-14 15:40 · Yahoo
Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet
2026-08-14 13:55 · Yahoo
Should Value Investors Buy Kamada (KMDA) Stock?
2026-08-13 13:40 · Yahoo
Kamada Ltd (KMDA) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
2026-08-12 23:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.